BioCryst Pharma (BCRX) Tops Q1 EPS by 2c
Tweet
Share
E-mailGet Alerts BCRX Hot Sheet
Price: $10.72 -3.51%
EPS Growth %: +6.7%
Financial Fact:
Royalties: 3.5M
Today's EPS Names:
CCEL, SLP, TMQ, More
EPS Growth %: +6.7%
Financial Fact:
Royalties: 3.5M
Today's EPS Names:
CCEL, SLP, TMQ, More
Join SI Premium – FREE
BioCryst Pharma (NASDAQ: BCRX) reported Q1 EPS of ($0.28), $0.02 better than the analyst estimate of ($0.30). Revenue for the quarter came in at $68.4 million versus the consensus estimate of $71.47 million.
For earnings history and earnings-related data on BioCryst Pharma (BCRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Key things to know ahead of SK Hynix’s blockbuster US listing
- EquipmentShare raises 2026 outlook, approves $500M buyback
- Angi Inc. names new chief accounting officer after resignation
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
